Share This Page
Drug Price Trends for DUAKLIR PRESSAIR
✉ Email this page to a colleague
Best Wholesale Price for DUAKLIR PRESSAIR
Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
---|---|---|---|---|---|---|---|---|
DUAKLIR PRESSAIR (60 DOSE) | Circassia Pharmaceuticals Inc. | 72124-0001-01 | 1 | 721.56 | 721.56000 | EACH | 2021-01-01 - 2025-03-29 | FSS |
DUAKLIR PRESSAIR (60 DOSE) | Circassia Pharmaceuticals Inc. | 72124-0001-01 | 1 | 744.80 | 744.80000 | EACH | 2020-03-30 - 2025-03-29 | FSS |
>Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Market Analysis and Price Projections for DUAKLIR PRESSAIR
DUAKLIR PRESSAIR, a combination of aclidinium bromide and formoterol fumarate, has made significant strides in the treatment of chronic obstructive pulmonary disease (COPD) since its launch in the United States in October 2019. As we delve into the market analysis and price projections for this innovative inhalation therapy, we'll explore its current market position, pricing trends, and future outlook.
The Rise of DUAKLIR PRESSAIR
DUAKLIR PRESSAIR entered the US market as a promising treatment option for COPD patients. Developed by Circassia Pharmaceuticals (now part of Covis Pharma), this fixed-dose LAMA/LABA combination offers a unique approach to COPD management[1].
Mechanism of Action
The drug combines two active ingredients:
- Aclidinium bromide: A long-acting muscarinic antagonist (LAMA)
- Formoterol fumarate: A long-acting beta agonist (LABA)
This dual-action approach provides comprehensive bronchodilation, addressing multiple aspects of COPD symptoms.
Administration and Dosage
DUAKLIR PRESSAIR is administered twice daily via a pre-loaded, breath-actuated Pressair multi-dose inhaler. The recommended dosage is one inhalation (400 mcg aclidinium bromide/12 mcg formoterol fumarate) twice daily[1][8].
Current Market Position
Since its launch, DUAKLIR PRESSAIR has carved out a niche in the competitive COPD treatment landscape. Its unique formulation and delivery system have contributed to its growing adoption among healthcare providers and patients.
Market Share
While specific market share data for DUAKLIR PRESSAIR is not provided in the search results, we can infer its position based on industry trends. The global inhalation drug delivery devices market, which includes products like DUAKLIR PRESSAIR, is projected to reach $20.7 billion by 2031, growing at a CAGR of 4.4%[9].
AstraZeneca ranked second with sales of its Bevespi Aerosphere, Duaklir Pressair, Symbicort and Tudorza Pressair products[9].
This ranking suggests that DUAKLIR PRESSAIR, as part of AstraZeneca's portfolio, holds a significant position in the market.
Pricing Analysis
Understanding the pricing structure of DUAKLIR PRESSAIR is crucial for both healthcare providers and patients. Let's break down the current pricing information available.
Retail Pricing
The average retail price for DUAKLIR PRESSAIR varies depending on the pharmacy and location:
- According to Drugs.com, the cost for one inhaler (60 metered doses) is approximately $316.06[2].
- GoodRx reports an average cost of $310.50 for the same quantity[10].
It's important to note that these prices are for cash-paying customers and may not reflect insurance coverage or discounts.
Factors Influencing Price
Several factors contribute to the pricing of DUAKLIR PRESSAIR:
- Research and development costs
- Manufacturing expenses
- Marketing and distribution
- Patent protection
- Competition in the COPD treatment market
Price Comparison
To put DUAKLIR PRESSAIR's pricing in perspective, let's compare it to other COPD treatments:
Drug | Average Price (60 doses) |
---|---|
DUAKLIR PRESSAIR | $316.06 |
Symbicort | $350-$400 |
Spiriva | $400-$450 |
While DUAKLIR PRESSAIR is not the least expensive option, its pricing is competitive within the COPD treatment market.
Patent Protection and Generic Entry
The patent landscape for DUAKLIR PRESSAIR plays a crucial role in its market exclusivity and future pricing.
Current Patent Status
DUAKLIR PRESSAIR is protected by four US patents[4]. These patents provide market exclusivity, preventing generic versions from entering the market prematurely.
Projected Generic Entry
Based on patent analysis by DrugPatentWatch, the earliest date for potential generic entry is February 10, 2025[4]. However, this date is subject to change due to various factors, including:
- Patent challenges
- Early generic licensing
- New patent filings
- Patent extensions
Market Projections
Looking ahead, several factors will influence the market trajectory of DUAKLIR PRESSAIR.
Growth Drivers
- Increasing COPD prevalence
- Aging population
- Rising awareness of respiratory diseases
- Technological advancements in inhalation devices
Potential Challenges
- Upcoming patent expiration
- Increasing competition from new COPD treatments
- Potential pricing pressures from healthcare reforms
Market Forecast
While specific projections for DUAKLIR PRESSAIR are not available, the overall inhalation drug delivery devices market is expected to grow significantly. The projected CAGR of 4.4% through 2031 suggests a positive outlook for products like DUAKLIR PRESSAIR[9].
Pricing Strategies and Future Outlook
As DUAKLIR PRESSAIR approaches its patent expiration, several pricing strategies may come into play.
Pre-Generic Entry Strategies
- Value-based pricing: Emphasizing the drug's efficacy and convenience
- Tiered pricing: Offering different pricing options based on patient needs
- Rebate programs: Providing discounts to maintain market share
Post-Generic Entry Scenarios
- Price reduction: Lowering prices to compete with generic versions
- Focus on brand loyalty: Emphasizing the reliability and familiarity of the brand
- Authorized generic: Launching an authorized generic version to capture part of the generic market
Impact of Healthcare Policies
Healthcare policies and reforms can significantly impact drug pricing and market dynamics.
Potential Policy Changes
- Drug pricing legislation
- Changes in Medicare and Medicaid coverage
- International reference pricing
Industry Response
Pharmaceutical companies, including DUAKLIR PRESSAIR's manufacturers, may need to adapt their pricing and marketing strategies in response to policy changes.
Patient Assistance Programs
To improve accessibility, manufacturers often offer patient assistance programs.
Current Programs
While specific programs for DUAKLIR PRESSAIR are not detailed in the search results, it's common for brand-name drugs to offer:
- Copay assistance
- Free trial programs
- Income-based discounts
Future of Patient Assistance
As the healthcare landscape evolves, patient assistance programs may become increasingly important in maintaining market share and patient access.
Global Market Considerations
While our focus has been primarily on the US market, it's important to consider DUAKLIR PRESSAIR's global presence.
International Availability
DUAKLIR PRESSAIR is approved worldwide, including in the European Union, under various brand names[1].
Price Variations
Pricing can vary significantly across different countries due to:
- Local healthcare systems
- Government regulations
- Economic factors
- Distribution costs
Competitive Landscape
Understanding DUAKLIR PRESSAIR's position relative to its competitors is crucial for market analysis.
Key Competitors
- Symbicort (AstraZeneca)
- Spiriva (Boehringer Ingelheim)
- Bevespi Aerosphere (AstraZeneca)
Competitive Advantages
DUAKLIR PRESSAIR's unique features include:
- Dual-action mechanism
- Breath-actuated inhaler design
- Twice-daily dosing
Future Innovations
The future of COPD treatment may bring new innovations that could impact DUAKLIR PRESSAIR's market position.
Potential Developments
- Triple therapy combinations
- Smart inhalers with digital tracking
- Personalized medicine approaches
Research and Development
Ongoing research in COPD treatment may lead to new formulations or delivery methods that could either complement or compete with DUAKLIR PRESSAIR.
Key Takeaways
- DUAKLIR PRESSAIR is a dual-action COPD treatment combining aclidinium bromide and formoterol fumarate.
- Current retail pricing ranges from $310 to $316 for a 60-dose inhaler.
- Patent protection is expected to last until February 2025, after which generic versions may enter the market.
- The global inhalation drug delivery devices market is projected to reach $20.7 billion by 2031, growing at a CAGR of 4.4%.
- Future pricing strategies may include value-based pricing, tiered pricing, and patient assistance programs.
- Healthcare policies and global market factors will play significant roles in shaping DUAKLIR PRESSAIR's future market position.
FAQs
-
What makes DUAKLIR PRESSAIR different from other COPD treatments? DUAKLIR PRESSAIR combines two active ingredients (aclidinium bromide and formoterol fumarate) in a single, breath-actuated inhaler, offering dual bronchodilation for COPD patients.
-
When is the patent for DUAKLIR PRESSAIR expected to expire? Based on current analysis, the earliest potential date for generic entry is February 10, 2025, though this may change due to various factors.
-
How does the price of DUAKLIR PRESSAIR compare to other COPD treatments? DUAKLIR PRESSAIR is competitively priced within the COPD treatment market, with an average retail price of around $316 for a 60-dose inhaler.
-
Are there any patient assistance programs available for DUAKLIR PRESSAIR? While specific programs aren't detailed in the search results, it's common for brand-name drugs to offer copay assistance and other patient support programs.
-
How might future healthcare policies affect the pricing of DUAKLIR PRESSAIR? Healthcare reforms, drug pricing legislation, and changes in Medicare and Medicaid coverage could all potentially impact the pricing and market dynamics of DUAKLIR PRESSAIR in the future.
Sources cited:
- https://respiratory-therapy.com/disorders-diseases/chronic-pulmonary-disorders/copd/copd-therapy-duaklir-pressair-now-available-in-us/
- https://www.drugs.com/price-guide/duaklir-pressair
- https://www.drugpatentwatch.com/p/tradename/DUAKLIR+PRESSAIR
- https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210595Orig1s000MultidisciplineR.pdf
- https://www.ihealthcareanalyst.com/global-inhalation-drug-delivery-devices-market/
- https://blocked.goodrx.com
More… ↓